Modality
Small Molecule
MOA
EGFRi
Target
AHR
Pathway
Ferroptosis
UC
Development Pipeline
Preclinical
~Aug 2022
→ ~Nov 2023
Phase 1
~Feb 2024
→ ~May 2025
Phase 2
Aug 2025
→ Nov 2030
Phase 2Current
NCT06258876
1,090 pts·UC
2025-08→2030-11·Recruiting
1,090 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-11-144.6y awayPh2 Data· UC
Trial Timeline
Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P2
Recruit…
Catalysts
Ph2 Data
2030-11-14 · 4.6y away
UC
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06258876 | Phase 2 | UC | Recruiting | 1090 | eGFR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2901 | Pfizer | Phase 2 | AHR | |
| Niranesiran | Johnson & Johnson | Phase 2 | KIF18A | |
| JNJ-5094 | Johnson & Johnson | Phase 2/3 | GIP-R | |
| AZN-1715 | AstraZeneca | Phase 3 | AHR | |
| GSK-2051 | GSK | Phase 1 | PSMA | |
| BAY-6520 | Bayer | Phase 2 | AHR | |
| GIL-8529 | Gilead Sciences | Phase 1/2 | JAK1 | |
| Semasacituzumab | Jazz Pharma | Phase 2 | AHR | |
| 207-2754 | Samsung Biologics | Phase 1/2 | KRASG12D | |
| Mavuratamab | Blueprint Medicines | NDA/BLA | BET |